Safety Reading Notes

Read safety context beside the research guide.

The THCV and target/pharmacology source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 42196303

PubMed For Dummies Article

THCV and target/pharmacology Evidence Review: the long-form source walk-through

Quick read
  • THCV and target/pharmacology currently has 23 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 42196303
  • The evidence classes most visible in the row language are mechanistic or pharmacological (17), and insufficient (6). PMID 32899626
  • The study-design language most visible in the row language is Animal study (12), Narrative or expert review (5), Cellular or in vitro study (1), and other mapped categories (2). PMID 40872492
  • The repeated topics are receptor, target, metabolic, or pharmacology mechanisms (23), which tells the reader where to start opening PubMed and DOI links. PMID 17828291

Start with the research question

THCV and target/pharmacology is built from 23 source-backed evidence row(s) and 23 research source(s). The current evidence classes read as mechanistic or pharmacological (17), and insufficient (6), and the study-design language most often reads as Animal study (12), Narrative or expert review (5), Cellular or in vitro study (1), and other mapped categories (2). PMID 42196303

The row-level question is not simply whether THCV and target/pharmacology is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are receptor, target, metabolic, or pharmacology mechanisms (23). PMID 32899626

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 27498155

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 21175579

Mechanistic evidence 17 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 28120231

Limits and uncertainty 6 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 25257544

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 16205722

Where this page has the most source density

The largest bucket surfaced for this page is receptor, target, metabolic, or pharmacology mechanisms: mechanistic or pharmacological. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is receptor, target, metabolic, or pharmacology mechanisms: insufficient, which gives readers another way to see what the literature repeatedly circles. PMID 42196303

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 32899626

Bucket chapters: what the literature is circling

receptor, target, metabolic, or pharmacology mechanisms: mechanistic or pharmacological

17 research sources 17 rows (761-782) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on receptor, target, metabolic, or pharmacology mechanisms: mechanistic or pharmacological. It currently draws from 17 research source(s), so the exact study type matters. PMID 42196303

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 42196303

  • Evidence row 761

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; ou... PMID 42196303

  • Evidence row 782

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure:... PMID 30074247

receptor, target, metabolic, or pharmacology mechanisms: insufficient

6 research sources 6 rows (760, 762, 763, 766, 767, 769) Evidence class: insufficient

This bucket summarizes source-backed rows focused on receptor, target, metabolic, or pharmacology mechanisms: insufficient. It currently draws from 6 research source(s), so the exact study type matters. PMID 32899626

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 32899626

  • Evidence row 760

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: rec... PMID 32899626

  • Evidence row 762

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: recepto... PMID 40872492

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (17 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 42196303

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 32899626

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 28087250
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 41008636
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 30170189

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 42196303

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 32899626

Source-reading checklist for THCV and target/pharmacology

  1. Open the linked PubMed or DOI record. PMID 31454413
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 20590571
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 17245367
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 23902479
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 18311186

Source Notes

THCV and target/pharmacology source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 760

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 32899626

    Evidence class: insufficient; Study design: Narrative or expert review. Source: It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets.
  2. Evidence row 761

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 42196303

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.
  3. Evidence row 762

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 40872492

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management.
  4. Evidence row 763

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 17828291

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
  5. Evidence row 764

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 27498155

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.
  6. Evidence row 765

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21175579

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
  7. Evidence row 766

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28120231

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Molecular Pharmacology of Phytocannabinoids.
  8. Evidence row 767

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Systematic review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25257544

    Evidence class: insufficient; Study design: Systematic review. Source: Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
  9. Evidence row 768

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 16205722

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
  10. Evidence row 769

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 28087250

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoids in the treatment of epilepsy.
  11. Evidence row 770

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 41008636

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.
  12. Evidence row 771

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 30170189

    Evidence class: mechanistic or pharmacological. Source: Δ9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6.
  13. Evidence row 772

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 31454413

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.
  14. Evidence row 773

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 20590571

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.
  15. Evidence row 774

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 17245367

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
  16. Evidence row 775

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 23902479

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
  17. Evidence row 776

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 18311186

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum.
  18. Evidence row 777

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (study design: Human clinical study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25542687

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.
  19. Evidence row 778

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 38691614

    Evidence class: mechanistic or pharmacological. Source: TRPV3 activation by different agonists accompanied by lipid dissociation from the vanilloid site.
  20. Evidence row 779

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 35714693

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Loratadine, an antihistaminic drug, suppresses the proliferation of endometrial stromal cells by inhibition of TRPV2.
  21. Evidence row 780

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 21726418

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
  22. Evidence row 781

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 34500785

    Evidence class: mechanistic or pharmacological. Source: An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models.
  23. Evidence row 782

    THCV modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 30074247

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.